Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...

Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This ...

Gilead’s potential investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor ...

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO ...

Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Gilead Sciences Inc. and LEO Pharma have partnered to accelerate the development and commercialization of LEO Pharma’s small ...

Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

Gilead Sciences and Danish dermatology specialist LEO Pharma announced a strategic partnership, marking another move outside ...

Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, ...

Katie McManigal, founder and medical director at Peak Health Institute, reflects on the clinic's journey: "Since 2021, Peak Health Institute has been at the forefront of functional ...

AVANT BIO, a growth equity firm dedicated to the enabling technologies transforming tomorrow's therapeutics, today announced Sebastien Latapie has been promoted to Partner. This promotion reflects Mr.